A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Dec 2019 Results of pooled Analysis of three Phase 2/3 Clinical Trials (NCT01487161, NCT02116972, NCT02357459) published in the Pain and Therapy
08 Nov 2017 Results of subgroup analysis (n=586) assessing the effectiveness of FX006 in patients with and without baseline inflammation using pooled data from three trials (NCT01487161, NCT02116972 and NCT02357459), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
02 Nov 2017 According to a Flexion Therapeutics media release, pooled analysis data of this and two other trials (see CT profiles 243924 and 234469) will be presented at the 2017 American College of Rheumatology (ACR) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com